Also known as: Myrbetriq
Myrbetriq is the brand name for mirabegron, a beta-3 adrenergic agonist used for overactive bladder in adults and neurogenic detrusor overactivity in eligible pediatric patients. The product includes extended-release tablets and granules for oral suspension with non-interchangeable dosing formats. It received initial U.S. approval in 2012.
Lupin Limited reported strong Q3 FY26 results with total sales of ₹71,005 million, up 26% year-over-year, and received US FDA approval for its pegfilgrastim biosimilar Armlupeg™, which has not yet been launched.
Zydus Lifesciences resolves US patent litigation with Astellas Pharma over generic Mirabegron for $120 million plus per-unit licensing fees through September 2027, enabling continued US marketing.
